AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
DiscussionFew approved treatments for COVID-19 are available such as dexamethasone, remdesivir and tocilizumab in hospitalised patients. The AGILE platform aims to rapidly identify new efficacious and safe treatments to help end the current global COVID-19 pandemic. We currently have three candidate specific trials within this platform study that are open to recruitment.Trial registrationEudraCT Number:2020-001860-27 14 March 2020ClinicalTrials.gov Identifier:NCT04746183 19 February 2021ISRCTN reference: 27106947 (Source: Trials)
Source: Trials - July 26, 2021 Category: Research Source Type: clinical trials
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa
Novavax ' Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 23, 2021 Category: Pharmaceuticals Source Type: clinical trials
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
GAITHERSBURG, Md., April 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 14, 2021 Category: Pharmaceuticals Source Type: clinical trials
AZD1222 Oxford Phase III Trials Interim Analysis Results Published in The Lancet
8 December 2020 -- Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet today, demonstrated that the vaccine is safe and effective at preventing... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 8, 2020 Category: Pharmaceuticals Source Type: clinical trials
Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial
AbstractObjectivesGeneral: To assess the safety, efficacy and dose response of convalescent plasma (CP) transfusion in severe COVID-19 patientsSpecific:a. To identify the appropriate effective dose of CP therapy in severe patientsb. To identify the efficacy of the therapy with their end point based on clinical improvement within seven days of treatment or until discharge whichever is later and in-hospital mortalityc. To assess the clinical improvement after CP transfusion in severe COVID-19 patientsd. To assess the laboratory improvement after CP transfusion in severe COVID-19 patientsTrial DesignThis is a multicentre, mul...
Source: Trials - October 26, 2020 Category: Research Source Type: clinical trials
COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in All Participants in Phase I/II Trial
20 July 2020 -- Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
COV001 is a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 20, 2020 Category: Pharmaceuticals Source Type: clinical trials
AstraZeneca to Supply Europe With Up To 400 Million Doses of Oxford University ’s COVID-19 Vaccine At No Profit
June 13, 2020 -- AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2020 Category: Pharmaceuticals Source Type: clinical trials
